Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

YTS 101

Next Previous
Drug Profile

YTS 101

Alternative Names: Anti-CD19 anti-CD 20 chimeric antigen receptor T cell therapy - China Immunotech; Anti-CD19/Anti-CD20 CAR-T cell therapy-China Immunotech; Anti-CD19/CD20 dual STAR-T cell therapy; CD19/CD20 dual CAR-T- China Immunotech; CD19/CD20 specific chimeric antigen receptor T-cell therapy - China Immunotech; Dual CAR-T cell therapy-China Immunotech; HXYT-001; YTS101

Latest Information Update: 28 Apr 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator China Immunotech
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported B-cell lymphoma; Leukaemia

Most Recent Events

  • 28 Apr 2023 No recent reports of development identified for phase-I development in B-cell lymphoma(In adolescents, In children, In the elderly, In infants, Second-line therapy or greater, In adults) in China (IV, Infusion)
  • 28 Mar 2023 No recent reports of development identified for phase-I development in Leukaemia(In adolescents, In children, In the elderly, In infants, Second-line therapy or greater, In adults) in China (IV, Infusion)
  • 23 Feb 2022 China Immunotech and Hebei Yanda Ludaopei Hospital plans a phase I trial for B-cell lymphoma (Second-line therapy or greater, In adolescents, In adults, In children, In infants, In the elderly) in China (IV), in May 2022 (NCT04260932)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top